top of page
CagriSema cagrilintide semaglutide blend 10mg vial Durham Peptides Canada research peptide

CagriSema Blend (Cagrilintide 5mg + Semaglutide 5mg) — 10mg

C$145.00Price
Quantity
Out of Stock

Research-grade CagriSema Blend, a dual-pathway peptide complex combining cagrilintide (5mg) and semaglutide (5mg) studied for amylin/calcitonin and GLP-1 receptor co-activation in metabolic research. 10mg total lyophilized powder, 99%+ purity per component verified by Janoshik Analytical via HPLC and mass spectrometry.


  • For laboratory research use only.

  • Not for human or veterinary use.

  • Not intended for diagnosis, treatment, cure, or prevention of any disease.

  • Use only in controlled laboratory settings by qualified personnel following appropriate safety procedures.

  • CagriSema is the research designation for a fixed-dose combination of two synthetic peptides — cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist). Originally developed by Novo Nordisk and currently progressing through Phase 3 clinical trials (REDEFINE 1, REDEFINE 2, REIMAGINE 2), this combination is among the most closely watched investigational compounds in modern metabolic research. Published Phase 3 data in the New England Journal of Medicine (2025) reported a 20.4% mean body weight reduction in the combination arm versus 3.0% with placebo over 68 weeks. Durham Peptides also carries Semaglutide and Tirzepatide individually for researchers interested in single-pathway or dual-agonist studies.


    BENEFITS


    • Dual-pathway research — amylin/calcitonin (cagrilintide) + GLP-1 (semaglutide) co-activation in one vial

    • Investigational reference — corresponds to Novo Nordisk's CagriSema clinical program

    • Convenience — two compounds in a single vial, eliminating dual-vial reconstitution

    • Synergy modeling — published Phase 3 data demonstrates combination effects exceed monotherapy

    • Once-weekly profile — both components feature fatty-acid lipidation supporting extended half-life research


    WHAT RESEARCHERS LOOK AT


    • Cagrilintide: amylin and calcitonin receptor activation, brainstem satiety pathways

    • Semaglutide: GLP-1 receptor agonism, hypothalamic appetite suppression

    • Combined vs. monotherapy comparisons in Phase 1-3 clinical research data

    • Glucagon suppression and gastric emptying delay (cagrilintide) vs. insulin secretion modulation (semaglutide)

    • Weight loss curves, lipid parameters, and cardiometabolic markers in published trials

bottom of page